Disclimer: Scopus and Crossref are registered trademark of respective companies.
This journal is member of Crossref.
Objective: To detected the amount of CD4 + Foxp3 + Treg cells in BD patients and to asses their correlation to disease activity.
Patients and methods: This study was applied on 60 patients with BD compared to 30 healthy group as control group from December 2020 to the end of May 2021. Their blood samples were collected to investigate blood concentrations of CD4 + marker and Foxp3 + Treg by using flow cytometer technique.
Results: The (median) of CD4 + Tcells percentage for the patient group was 10.9%, significantly higher than that of the control group 8.30% ranged (0.80–17.30). While there was a highly significant increase in the (median) 26.20% of CD4 + Foxp3 + Tcells in the patients group in comparison with the control group median (4.65%). The Treg cells determined by the proportion of CD4 + Foxp3 + in all CD4 + Tcells showed a significant increase in the (median) for patient group (10.80% ) if compared with the control group (8.50% ) (p=0.045). A significant decrease CD4 + in monocyte was detected in patient group (8.50%) in comparison to control group (12.70%)(p=0.003).
Conclusion: Patients with BD had more CD4 + , Foxp3 + Treg cells than the control group did. Monocyte levels were lower in BD patients. There was a link between disease activity and Treg concentration.
High-performance liquid chromatography (HPLC) was used to conduct quantitative and qualitative analyses of the alkaloids components and compare them to their levels in the plant. Significant variations were seen at the higher (400 mg/l) concentration of NiO NPs for boosting alkaloids molecules.
Method: A total of 80 patients with acromegaly are enrolled in the study from July/2019 to April/2020. Their age range (20–72 years). They are 47 men and 33 women. Their selection was based on their visits to NDC on the basis of prescheduled appointments to be given their monthly injections of long-acting octreotide (LAR) and to be examined clinically plus conducting various types of hormonal studies and biochemical workups to assess their response to treatment on the following parameters: Adenoma size, IGF-1 and GH and its correlation with octreotide dose.
Results: It is a cross-sectional comparative clinical trial study of 80 patients with acromegaly. Mean of age was 46.7 ± 12.4 years’, and their age range (20–72 year) minimum and maximum-year-old. Mean duration of taking drug was 8 ± 6.7 years. The mean of total LRA injection was (1073.6 ± 666.2 mg). 58.75% of patients were male while 41.25% were female. 46.25% of patients do not have transsphenoidal direct surgery, but 46.25% undergo one surgery, 7.5% undergo two transsphenoidal hypophysectomies. 87.5% of patients have no gamma knife while 12.5% have gamma knife radiosurgery. Conclusion: Acromegaly is a multi systemic disease that should be diagnosed and treated as early as possible to prevent complications and improve mortality rates.
This journal is present in UGC approved List of Journals for the purpose of Career Advancement Scheme (CAS) and Direct Recruitment of Teachers and other academic staff as required under the UGC (Minimum Qualifications for Appointment of Teachers and other Academic Staff in Universities and Colleges)
International Journal of Pharmaceutical Quality Assurance
International Journal of Pharmaceutical and Clinical Research
International Journal of Pharmacognosy and Phytochemical Research
International Journal of Current Pharmaceutical Review and Research
International Journal of Toxicological and Pharmacological Research
The publication is licensed under Creative Commons License View Legal Published by Dr. Yashwant Research Labs Pvt. Ltd. on behalf of International Society for Science and Nature